Sharon Rosenzweig-Lipson
Rosenzweig-Lipson helped test aged-rat memory rescue and OSK vision recovery in glaucomatous mice. Useful preclinical longevity-adjacent signal, not proof of human life extension. Science, not fairy dust.
12 / 100operatorscientistScoring AI engine · v0.4.0
Role
operatorhigh confidence
The strongest evidence is that she is the CSO of LiFE Biosciences and is running the eye reprogramming program toward a Phase 1 trial. That is a senior executive operating role in a longevity venture she is not shown to have founded, and it is the clearest channel of impact in this record.
also: scientist
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Evidence is still sparse for this hero. Scores are shown with low-confidence warnings until more source material is harvested.
Future vision
1.0/ 10
The dimension applies, but the supplied evidence contains no public vision statements, destination quotes, theory endorsements, or path/timeline/risk framing about ending aging, reversing biological decline, or materially extending healthy lifespan. The only aging-relevant signal is participation in or authorship of aging-related scientific work, which does not by itself establish an articulated future vision.
low confidence
Scientific impact
2.0/ 10
Scientific impact applies, but the primary citation signal is very weak: the provided OpenAlex record shows h-index 0, i10-index 0, 0 citations, and only 1 indexed work. The peer-reviewed papers indicate some direct preclinical neuroscience contributions, including aged-rat cognition and schizophrenia-model cognition studies, but the evidence does not show field-shaping citation influence or clinical/translational impact.
medium confidence
Capital deployed
N/A
The evidence supports scientific/academic involvement in aging-related work, but provides no credible indication of personal, philanthropic, investment, fund-allocation, or institutional capital deployment. This dimension is therefore not applicable on the supplied record.
No evidence provided that Rosenzweig-Lipson deploys capital, philanthropy, fund allocations, or institution-building resources toward longevity.
medium confidence
Strategic taste
2.0/ 10
The dimension is applicable, but the provided evidence contains almost no direct strategy, deployment, investment, donation, or organization-building record. The strongest signal is a scientific coauthorship on a potentially contrarian therapeutic approach for age-related cognitive impairment, but there is no evidence that Rosenzweig-Lipson personally formed the thesis, made early bets, or counterfactually opened a path for the longevity field.
low confidence
Field creation
0.0/ 10
The provided evidence does not show that Sharon Rosenzweig-Lipson founded organizations, created programs, built communities, established protocols, or opened funding paths that made longevity work more legible or possible for others. The evidence is limited to scientific coauthorship and citation metadata, which may relate to scientific contribution but not field creation.
medium confidence
Bravery and conviction
0.0/ 10
The provided evidence shows scientific coauthorship on aging-adjacent and age-related disease research, but no evidence of public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, large personal bet, or self-experimentation. Bravery/conviction is applicable, but unsupported by the supplied record.
medium confidence
Multiplier effect
2.0/ 10
The dimension applies, but the provided evidence shows little direct second-order leverage. Rosenzweig-Lipson appears as a collaborator/coauthor on aging-adjacent and longevity biotechnology publications, including a large multi-author ARDD-related review, but there is no evidence of founding organizations, attracting capital, building programs, shaping policy, creating follow-on projects, or broadly mobilizing talent beyond direct scientific participation.
low confidence
Vision
Destination
Sharon’s running the programs to reprogram the human eye to improve vision.
Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.
I’m excited to connect and discuss the innovations driving the future of human healthspan.
Partial Epigenetic Programming and the promise of turning back aging Sharon Rosenzweig-Lipson, PhD (Life Biosciences)
It’s inspiring to see the momentum behind developing interventions that target the biology of aging to improve healthspan.
Path
The scientific dialogue at the summit reinforced the importance of bringing scientists, clinicians, economists and regulators together to discuss this rapidly growing and evolving Healthspan field.
She shares insights into our OSK-based partial epigenetic reprogramming platform
She shares insights into our OSK-based partial epigenetic reprogramming platform
I’ll be presenting on “Rewriting the Rules of Aging” at 1:15pm on December 9, where I’ll share how we at Life Biosciences are approaching reversing age-related disease and why targeting core aging mechanisms may redefine how we prevent chronic disease.
I was proud to share Life Biosciences’ latest work on Partial Epigenetic Reprogramming and its potential to address age-related diseases in a panel discussion at the conference.
Publicly endorses ER-100 rejuvenates optic nerve cells to treat optic neuropathiesPublicly endorses Cellular rejuvenation may address multiple diseases of agingPublicly endorses Partial epigenetic reprogramming restores youthful cellular functionPublicly endorses Targeting aging biology can treat multiple diseases of agingPublicly endorses Optic neuropathy can be treated by rejuvenating eye cellsPublicly endorses Cellular rejuvenation can treat optic neuropathiesPublicly endorses Reversing cellular aging may address multiple diseases of agingPublicly endorses Partial epigenetic reprogramming restores youthful cell statePublicly endorses OSK partial epigenetic restoration rejuvenates aged cellsPublicly endorses OSK gene therapy can rejuvenate diseased optic nerve cells
Strategy
No strategy evidence was available for Sharon Rosenzweig-Lipson. Her investment, donation, and organization-founding records are unsupported in the provided material. As a result, her longevity thesis, stage preference, focus areas, geography, risk appetite, and time horizon are unknown. No notable bets or collaborators can be cited from the evidence provided.
UnknownUnknown
Portfolio
Investments
No public rows yet.
Donations
No public rows yet.
Organizations founded
No public rows yet.
Scientific output
h-index0
Citations-
Papers10
Trials0
Belief evolution
Self-experimentation
Connections
Companies
Collaborators and lineage
No public rows yet.
Criticisms